

# HIV | SURVEILLANCE DATA TABLES



**Core Indicators for Monitoring the Ending the HIV Epidemic Initiative (*Preliminary Data*):**

**National HIV Surveillance System Data Reported through September 2023; and Preexposure Prophylaxis (PrEP) Data Reported through June 2023**



**Centers for Disease  
Control and Prevention**  
National Center for HIV,  
Viral Hepatitis, STD, and  
TB Prevention

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through September 2023 and preexposure prophylaxis (PrEP) data reported through June 2023.

*HIV Surveillance Data Tables* is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

### **Suggested citation**

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through September 2023; and preexposure prophylaxis (PrEP) data reported through June 2023. *HIV Surveillance Data Tables* 2023;4(4). <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/>. Published December 2023. Accessed [date].

**On the Web:** <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/>

### **Confidential information, referrals, and educational material on HIV infection**

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://wwwn.cdc.gov/dcs/ContactUs/Form>

### **Acknowledgments**

This issue of *HIV Surveillance Data Tables* was prepared by the following staff and contractors of the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC: Juliet Morales, Anna Satcher Johnson, Zanetta Gant Sumner, Ya-lin Huang, Weiming Zhu, Emily Zhu, Xueyuan Dong, Nan Hong, Chan Jin, Chelsea Walker, Pei Hou, Xiaohong Hu, Jianmin Li, Lei Yu, Wei Wei, Eli Krebs, Khang Nguyen, Norma Harris, Stacy Cohen, and Michael Friend (editing and desktop publishing).

The Content and Infrastructure Team of the Prevention Communications Branch are acknowledged for their contributions to the report website.

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

<b>Technical Notes</b>	4
<b>References</b>	7
<b>Tables</b>	
1a Diagnoses of HIV infection among persons aged $\geq 13$ years, by selected characteristics, January 2022 through September 2023—United States (preliminary)	8
1b Diagnoses of HIV infection among persons aged $\geq 13$ years, by selected characteristics, January 2022 through September 2023—United States and 6 dependent areas (preliminary)	9
1c Diagnoses of HIV infection among persons aged $\geq 13$ years, by area of residence, January 2022 through September 2023—United States and 6 dependent areas (preliminary)	10
1d Diagnoses of HIV infection among persons aged $\geq 13$ years, by selected characteristics, January 2022 through September 2023—United States (preliminary)Diagnoses of HIV infection among persons aged $\geq 13$ years, by area of residence, January 2022 through September 2023—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	11
2a Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged $\geq 13$ years, by selected characteristics, January 2022 through June 2023—47 states and the District of Columbia (preliminary)	13
2b Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged $\geq 13$ years, by area of residence, January 2022 through June 2023—47 states and the District of Columbia (preliminary)	15
2c Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged $\geq 13$ years, by area of residence, January 2022 through June 2023—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	16
3a Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged $\geq 16$ years, by selected characteristics—United States	19
3b Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged $\geq 16$ years, by area of residence—United States and Puerto Rico (preliminary)	22
3c Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged $\geq 16$ years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	27
4 Ending the HIV Epidemic Phase I jurisdictions	37

# Technical Notes

The *Ending the HIV Epidemic in the U.S.* (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and by 90% by 2030. The Centers for Disease Control and Prevention (CDC) routinely releases *HIV Surveillance Data Tables* on the core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the *Core Indicators for Monitoring the Ending the HIV Epidemic Initiative* report, available at <https://www.cdc.gov/hiv/pdf/library/reports/surveillance-data-tables/vol-1-no-1/cdc-hiv-surveillance-tables-vol-1-no-1.pdf>.

The tables included in this report provide *preliminary* data on HIV diagnoses and linkage to HIV medical care for the years 2022 and 2023 based on cases reported to CDC as of September 2023. Data on preexposure prophylaxis (PrEP) coverage are provided for the years 2019, 2020, 2021, 2022, and 2023 (preliminary). Data for the 3 indicators are provided at the national, state, and county levels (EHE Phase I jurisdictions only). See Tabulation and Presentation of Data for details on how the indicators are calculated. More information on HIV surveillance practices and limitations, demographic information, and geographic designations can be found in the Technical Notes of the *HIV Surveillance Report, 2021*, available at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-34/>.

## TABULATION AND PRESENTATION OF DATA

### Diagnoses of HIV Infection

Diagnoses of HIV infection are the numbers of persons aged  $\geq 13$  years with HIV diagnosed during January 2022 through September 2023 (Tables 1a–d). Data presented were reported (after the removal of personally identifiable information) to CDC.

An evaluation of surveillance data (2016–2020 diagnoses) found that, on average, approximately 80% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 98% of HIV diagnoses are reported to CDC by the end of the following year. Data for years 2022 and 2023 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on counting diagnoses of HIV infection can be found in the *HIV Surveillance Report, 2021*, available at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-34/>.

### Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged  $\geq 13$  years whose infection was diagnosed during January 2022 through June 2023 and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 2a–c). The numerator is the number of persons aged  $\geq 13$  years whose HIV infection was diagnosed during January 2022 through June 2023 and who had  $\geq 1$  CD4 T-lymphocyte (CD4) or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged  $\geq 13$  years whose HIV infection was diagnosed during January 2022 through June 2023. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to

the National HIV Surveillance System (NHSS); therefore, data on linkage to HIV medical care in these surveillance tables are for persons whose HIV infection was diagnosed during January 2022 through June 2023 and was reported to NHSS through September 2023. Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

More information on calculating linkage to care can be found in *Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2021*, available at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-28-no-4/>.

## Preexposure Prophylaxis Coverage

Preexposure prophylaxis (PrEP) coverage, reported as a percentage, is defined as the number of persons aged  $\geq 16$  years classified as having been prescribed PrEP during the specified year divided by the estimated number of persons aged  $\geq 16$  years who had indications for PrEP during the specified year (Tables 3a–c). PrEP coverage is an EHE indicator that is not a reportable disease or condition and is not reported to NHSS. Multiple data sources, described below, are used to calculate PrEP coverage. Please note that changes in the total percentage across each report occur because data are received at multiple points through the year; readers should note the period for which the data are calculated and use caution when comparing partial-year data to full-year data.

Please use caution when interpreting PrEP data. Different data sources were used in the numerator and denominator to calculate PrEP coverage.

### Persons prescribed PrEP

National pharmacy data from the IQVIA Real World Data—Longitudinal Prescriptions database (hereafter, IQVIA database) are used to classify persons aged  $\geq 16$  years who have been prescribed PrEP in a specific year. The IQVIA database captures prescriptions from all payers and represents approximately 94% of all prescriptions from retail pharmacies and 74% from mail-order outlets in the United States. The database does not include prescriptions from some closed health care systems that do not make their prescription data available to IQVIA. Therefore, these are minimum estimates of PrEP coverage. The annual number of persons classified as having been prescribed PrEP was based on a validated algorithm that discerns whether tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) was prescribed for PrEP after excluding prescriptions for HIV treatment, hepatitis B treatment, or HIV postexposure prophylaxis [2–4]. Tenofovir alafenamide and emtricitabine (TAF/FTC) was approved as an alternative drug for PrEP by the U.S. Food and Drug Administration (FDA) in October 2019. Long-acting injectable cabotegravir (CAB-LA) was approved by the FDA as an additional prevention option for PrEP in December 2021. After the respective approvals, TAF/FTC and CAB-LA were included in the algorithm to classify the number of persons prescribed PrEP.

The number of persons classified as having been prescribed PrEP is reported by sex, age group, and race/ethnicity. Transmission category data are not available in the IQVIA database, and race/ethnicity data are available for  $<40\%$  of persons with PrEP prescriptions. Please use caution when interpreting PrEP data by race/ethnicity. Race/ethnicity categories available in the IQVIA database include White, Black/African American, Hispanic/Latino, and other. The number of persons prescribed PrEP for each racial/ethnic group presented in this report was extrapolated by applying the racial/ethnic distribution of known records to those for which data on race/ethnicity were unknown.

## Geographic designations

In the IQVIA database, a person's location is reported as a 3-digit ZIP code prefix (hereafter, ZIP3) assigned by the U.S. Postal Service. To estimate the number of persons prescribed PrEP at the state or county level, a probability-based approach is used to crosswalk between ZIP3s and states/counties by using data from (a) the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates by ZIP Code Tabulation Areas (ZCTAs) [5], and (b) the U.S. Department of Housing and Urban Development's ZIP Code Crosswalk Files [6]. Because of reliability concerns, subnational estimates of <40 are not included.

## Persons with PrEP indications

U.S. Census Bureau files and their ACS were used to estimate the number of gay, bisexual, and other men who have sex with men (MSM) in a jurisdiction [7, 8]. Next, behavioral data from the National Health and Nutrition Examination Survey (NHANES) were used to estimate the proportion of HIV-negative MSM with indications for PrEP [9].

The number of HIV-negative MSM with indications for PrEP was multiplied by the ratio of percentage of diagnoses during the specified year attributed to other major transmission risk groups compared to the percentage among MSM in a given state or county. The estimated numbers of persons with indications for PrEP in the 3 major transmission risk groups (MSM, heterosexuals, persons who inject drugs) in each jurisdiction were then summed to yield a state- or county-specific estimate. State estimates were then summed for a national total of persons with indications for PrEP [7]. Jurisdictional estimates were rounded to the nearest 10.

The tables included in this report provide updated data on PrEP coverage for the years 2019–2023 by using the IQVIA data reported through June 2023. IQVIA conducts data quality assurance activities. As a result, the number of persons classified as having been prescribed PrEP in a given year might change from time to time. The impact of the changes may vary by demographic category nationally and by jurisdiction. The data sources used to estimate the number of persons with indications for PrEP have different schedules of availability. Consequently, the availability of a denominator lags the availability of a numerator. PrEP coverage data with a lagged denominator are considered preliminary.

For this release of *HIV Surveillance Data Tables*, 2018 denominators were used for 2019 through 2023 PrEP coverage data; consequently, 2019 through 2023 PrEP coverage data are considered preliminary. In addition to being preliminary, data for the year 2020 should be interpreted with awareness of the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions [10].

More information on calculating PrEP coverage can be found in *Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2021*, available at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-28-no-4/>.

# References

1. HHS. What is *Ending the HIV Epidemic in the U.S.*? <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>. Updated July 2, 2022. Accessed November 9, 2023.
2. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014. *Clin Infect Dis* 2017;64(2):144–149. doi:10.1093/cid/ciw701
3. CDC [Huang YA, Zhu W, Smith DK, Harris N, Hoover KW]. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. *MMWR* 2018;67(41):1147–1150. doi:10.15585/mmwr.mm6741a3
4. Furukawa NW, Smith DK, Gonzalez CJ, et al. Evaluation of algorithms used for PrEP surveillance using a reference population from New York City, July 2016–June 2018. *Public Health Rep* 2020;135(2):202–210. doi:10.1177/0033354920904085
5. U.S. Census Bureau. American Community Survey 5-year data (2009–2021). <https://www.census.gov/data/developers/data-sets/acs-5year.2019.html>. Updated June 2023. Accessed November 9, 2023.
6. U.S. Department of Housing and Urban Development (HUD). HUD USPS ZIP code crosswalk files. [https://www.huduser.gov/portal/datasets/usps\\_crosswalk.html](https://www.huduser.gov/portal/datasets/usps_crosswalk.html). Updated August 2022. Accessed November 9, 2023.
7. Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the population sizes of men who have sex with men in US states and counties using data from the American Community Survey. *JMIR Public Health Surveill* 2016;2(1):e14. doi:10.2196/publichealth.5365
8. Purcell DW, Johnson CH, Lansky A, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. *Open AIDS J* 2012;6:98–107. doi:10.2174/1874613601206010098
9. CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. *MMWR* 2015;64(46):1291–1295. doi:10.15585/mmwr.mm6446a4
10. Huang YA, Zhu W, Wiener J, Kourtis AP, Hall HI, Hoover KW. Impact of COVID-19 on HIV preexposure prophylaxis prescriptions in the United States—a time series analysis. *Clin Infect Dis* 2022:ciac038. doi:10.1093/cid/ciac038

**Table 1a. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2022 through September 2023—United States (preliminary)**

	No.	No.
	2022	2023 (January–September)
<b>Gender</b>		
Male	29,621	19,925
Female	6,933	4,786
Transgender woman <sup>a</sup>	844	418
Transgender man <sup>a</sup>	59	36
Additional gender identity <sup>b</sup>	64	57
<b>Age at diagnosis (yr)</b>		
13–24	6,966	4,427
25–34	13,990	9,271
35–44	8,278	5,805
45–54	4,552	3,116
≥55	3,735	2,603
<b>Race/ethnicity</b>		
American Indian/Alaska Native	218	128
Asian	795	493
Black/African American	14,570	10,086
Hispanic/Latino <sup>c</sup>	11,733	7,726
Native Hawaiian/other Pacific Islander	84	43
White	9,126	6,249
Multiracial	995	497
<b>Transmission category<sup>d</sup></b>		
Male-to-male sexual contact <sup>e</sup>	25,294	16,984
Injection drug use <sup>f</sup>		
Male	1,417	855
Female	1,181	686
Male-to-male sexual contact <sup>e</sup> and injection drug use <sup>f</sup>	1,292	754
Heterosexual contact <sup>g</sup>		
Male	2,488	1,775
Female	5,748	4,084
Other <sup>h</sup>		
Male	33	29
Female	69	54
<b>Region of residence<sup>i</sup></b>		
Northeast	5,057	3,034
Midwest	4,846	3,372
South	19,928	14,217
West	7,690	4,599
<b>Total</b>	<b>37,521</b>	<b>25,222</b>

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through September 2023, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

<sup>a</sup> “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

<sup>b</sup> Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

<sup>c</sup> Hispanic/Latino persons can be of any race.

<sup>d</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

<sup>e</sup> Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

<sup>f</sup> Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

<sup>g</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>h</sup> Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

<sup>i</sup> Data are based on residence at time of diagnosis of HIV infection.

**Table 1b. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2022 through September 2023—United States and 6 dependent areas (preliminary)**

	No. 2022	No. 2023 (January–September)
<b>Gender</b>		
Male	29,929	20,127
Female	6,998	4,822
Transgender woman <sup>a</sup>	846	419
Transgender man <sup>a</sup>	59	36
Additional gender identity <sup>b</sup>	64	57
<b>Age at diagnosis (yr)</b>		
13–24	7,017	4,451
25–34	14,117	9,359
35–44	8,359	5,849
45–54	4,611	3,156
≥55	3,792	2,646
<b>Race/ethnicity</b>		
American Indian/Alaska Native	218	128
Asian	795	493
Black/African American	14,576	10,087
Hispanic/Latino <sup>c</sup>	12,092	7,957
Native Hawaiian/other Pacific Islander	84	43
White	9,136	6,255
Multiracial	995	498
<b>Transmission category<sup>d</sup></b>		
Male-to-male sexual contact <sup>e</sup>	25,521	17,131
Injection drug use <sup>f</sup>		
Male	1,443	866
Female	1,186	687
Male-to-male sexual contact <sup>e</sup> and injection drug use <sup>f</sup>	1,297	754
Heterosexual contact <sup>g</sup>		
Male	2,540	1,819
Female	5,806	4,119
Other <sup>h</sup>		
Male	33	29
Female	70	55
<b>Region of residence<sup>i</sup></b>		
Northeast	5,057	3,034
Midwest	4,846	3,372
South	19,928	14,217
West	7,690	4,599
U.S. dependent areas	375	239
<b>Total</b>	<b>37,896</b>	<b>25,461</b>

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through September 2023, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. The 6 U.S. dependent areas are American Samoa, Guam, Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin Islands.

<sup>a</sup> “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

<sup>b</sup> Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

<sup>c</sup> Hispanic/Latino persons can be of any race.

<sup>d</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

<sup>e</sup> Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

<sup>f</sup> Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

<sup>g</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>h</sup> Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

<sup>i</sup> Data are based on residence at time of diagnosis of HIV infection.

**Table 1c. Diagnoses of HIV infection among persons aged  $\geq$  13 years, by area of residence, January 2022 through September 2023—United States and 6 dependent areas (preliminary)**

Area of residence	No.	No.
	2022	2023 (January–September)
Alabama	642	364
Alaska	38	19
Arizona	874	552
Arkansas	307	252
California	4,693	2,712
Colorado	430	268
Connecticut	224	108
Delaware	128	75
District of Columbia	183	126
Florida	4,473	3,913
Georgia	2,558	1,539
Hawaii	77	34
Idaho	42	22
Illinois	1,278	722
Indiana	610	448
Iowa	119	102
Kansas	133	104
Kentucky	406	272
Louisiana	858	650
Maine	40	23
Maryland	749	469
Massachusetts	437	207
Michigan	630	498
Minnesota	261	233
Mississippi	432	275
Missouri	509	385
Montana	11	14
Nebraska	89	64
Nevada	533	362
New Hampshire	28	20
New Jersey	1,090	595
New Mexico	77	14
New York	2,219	1,412
North Carolina	1,353	1,011
North Dakota	34	6
Ohio	853	581
Oklahoma	394	176
Oregon	249	150
Pennsylvania	949	633
Rhode Island	66	29
South Carolina	722	598
South Dakota	40	34
Tennessee	860	598
Texas	4,892	3,224
Utah	151	114
Vermont	4	7
Virginia	832	600
Washington	502	323
West Virginia	139	75
Wisconsin	290	195
Wyoming	13	15
<b>Subtotal</b>	<b>37,521</b>	<b>25,222</b>
<b>U.S. dependent areas</b>		
American Samoa	0	0
Guam	0	0
Northern Mariana Islands	0	0
Puerto Rico	361	235
Republic of Palau	0	0
U.S. Virgin Islands	14	4
<b>Subtotal</b>	<b>375</b>	<b>239</b>
<b>Total</b>	<b>37,896</b>	<b>25,461</b>

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

*Note.* Data are based on residence at the time of diagnosis of HIV infection. Data are for cases reported to CDC through September 2023, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

**Table 1d. Diagnoses of HIV infection among persons aged  $\geq$  13 years, by area of residence, January 2022 through September 2023—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)**

Area of residence	No.	
	2022	2023 (January–September)
<b>Arizona</b>		
Maricopa County	587	369
<b>California</b>		
Alameda County	201	127
Los Angeles County	1,496	878
Orange County	254	183
Riverside County	313	161
Sacramento County	194	90
San Bernardino County	286	162
San Diego County	391	194
San Francisco County	213	136
<b>District of Columbia</b>	183	126
<b>Florida</b>		
Broward County	598	520
Duval County	287	231
Hillsborough County	297	306
Miami-Dade County	1,095	928
Orange County	424	394
Palm Beach County	294	210
Pinellas County	116	134
<b>Georgia</b>		
Cobb County	176	121
DeKalb County	362	202
Fulton County	525	294
Gwinnett County	220	117
<b>Illinois</b>		
Cook County	855	473
<b>Indiana</b>		
Marion County	248	181
<b>Louisiana</b>		
East Baton Rouge Parish	132	101
Orleans Parish	126	86
<b>Maryland</b>		
Baltimore City	161	103
Montgomery County	106	67
Prince George's County	251	136
<b>Massachusetts</b>		
Suffolk County	116	60
<b>Michigan</b>		
Wayne County	247	206
<b>Nevada</b>		
Clark County	488	320
<b>New Jersey</b>		
Essex County	233	126
Hudson County	168	70

**Table 1d. Diagnoses of HIV infection among persons aged  $\geq 13$  years, by area of residence, January 2022 through September 2023—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)**

Area of residence	No.	No.
	2022 ( <i>cont</i> )	2023 (January–September) ( <i>cont</i> )
<b>New York</b>		
Bronx County	395	231
Kings County	477	267
New York County	326	196
Queens County	370	262
<b>North Carolina</b>		
Mecklenburg County	276	204
<b>Ohio</b>		
Cuyahoga County	118	110
Franklin County	193	140
Hamilton County	93	60
<b>Pennsylvania</b>		
Philadelphia County	376	256
<b>Puerto Rico</b>		
San Juan Municipio	110	57
<b>Tennessee</b>		
Shelby County	339	209
<b>Texas</b>		
Bexar County	353	204
Dallas County	911	569
Harris County	1,278	883
Tarrant County	331	240
Travis County	244	164
<b>Washington</b>		
King County	259	148

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

*Note.* Data are based on residence at the time of diagnosis of HIV infection. Data are for cases reported to CDC through September 2023, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

**Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2022 through June 2023—47 states and the District of Columbia (preliminary)**

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	<b>2022</b>				
<b>Gender</b>					
Male	27,980	22,957	82.0	5,023	18.0
Female	6,525	5,242	80.3	1,283	19.7
Transgender woman <sup>a</sup>	816	674	82.6	142	17.4
Transgender man <sup>a</sup>	56	50	89.3	6	10.7
Additional gender identity <sup>b</sup>	63	62	98.4	1	1.6
<b>Age at diagnosis (yr)</b>					
13–24	6,650	5,361	80.6	1,289	19.4
25–34	13,164	10,742	81.6	2,422	18.4
35–44	7,794	6,412	82.3	1,382	17.7
45–54	4,316	3,550	82.3	766	17.7
≥55	3,516	2,920	83.0	596	17.0
<b>Race/ethnicity</b>					
American Indian/Alaska Native	214	167	78.0	47	22.0
Asian	757	674	89.0	83	11.0
Black/African American	13,817	10,833	78.4	2,984	21.6
Hispanic/Latino <sup>c</sup>	11,006	9,375	85.2	1,631	14.8
Native Hawaiian/other Pacific Islander	84	63	75.0	21	25.0
White	8,638	7,113	82.3	1,525	17.7
Multiracial	924	760	82.3	164	17.7
<b>Transmission category<sup>d</sup></b>					
Male-to-male sexual contact <sup>e</sup>	24,021	19,856	82.7	4,166	17.3
Injection drug use <sup>f</sup>	2,387	1,817	76.1	571	23.9
Male	1,289	974	75.6	315	24.4
Female	1,099	843	76.7	256	23.3
Male-to-male sexual contact <sup>e</sup> and injection drug use <sup>f</sup>	1,229	991	80.7	237	19.3
Heterosexual contact <sup>g</sup>	7,710	6,245	81.0	1,466	19.0
Male	2,287	1,845	80.7	442	19.3
Female	5,424	4,400	81.1	1,023	18.9
<b>Total<sup>h</sup></b>	<b>35,440</b>	<b>28,985</b>	<b>81.8</b>	<b>6,455</b>	<b>18.2</b>

**Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2022 through June 2023—47 states and the District of Columbia (preliminary) (cont)**

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
<b>2023 (January–June)</b>					
<b>Gender</b>					
Male	14,605	12,135	83.1	2,470	16.9
Female	3,439	2,804	81.5	635	18.5
Transgender woman <sup>a</sup>	321	294	91.6	27	8.4
Transgender man <sup>a</sup>	28	26	92.9	2	7.1
Additional gender identity <sup>b</sup>	46	40	87.0	6	13.0
<b>Age at diagnosis (yr)</b>					
13–24	3,259	2,663	81.7	596	18.3
25–34	6,743	5,595	83.0	1,148	17.0
35–44	4,280	3,553	83.0	727	17.0
45–54	2,292	1,921	83.8	371	16.2
≥55	1,865	1,567	84.0	298	16.0
<b>Race/ethnicity</b>					
American Indian/Alaska Native	93	75	80.6	18	19.4
Asian	364	303	83.2	61	16.8
Black/African American	7,287	5,817	79.8	1,470	20.2
Hispanic/Latino <sup>c</sup>	5,717	4,935	86.3	782	13.7
Native Hawaiian/other Pacific Islander	31	27	87.1	4	12.9
White	4,559	3,808	83.5	751	16.5
Multiracial	388	334	86.1	54	13.9
<b>Transmission category<sup>d</sup></b>					
Male-to-male sexual contact <sup>e</sup>	12,496	10,470	83.8	2,026	16.2
Injection drug use <sup>f</sup>	1,118	889	79.5	229	20.5
Male	618	487	78.8	131	21.2
Female	500	402	80.4	98	19.6
Male-to-male sexual contact <sup>e</sup> and injection drug use <sup>f</sup>	557	449	80.7	108	19.3
Heterosexual contact <sup>g</sup>	4,210	3,441	81.7	769	18.3
Male	1,277	1,042	81.6	234	18.4
Female	2,933	2,399	81.8	534	18.2
<b>Total<sup>h</sup></b>	<b>18,439</b>	<b>15,299</b>	<b>83.0</b>	<b>3,140</b>	<b>17.0</b>

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/ $\mu$ L) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of  $\geq 1$  CD4 or VL tests  $\leq 1$  month after HIV diagnosis. Data are for cases reported to CDC through September 2023, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Data are based on residence at time of diagnosis of HIV infection. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

<sup>a</sup> “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

<sup>b</sup> Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

<sup>c</sup> Hispanic/Latino persons can be of any race.

<sup>d</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

<sup>e</sup> Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

<sup>f</sup> Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

<sup>g</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>h</sup> Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

**Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2022 through June 2023—47 states and the District of Columbia (preliminary)**

Area of residence	Total diagnoses			Total diagnoses			Total diagnoses			
	No.	≥1 CD4 or VL tests		No CD4 or VL test		No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%		No.	%	No.	%
	2022					2023 (January–June)				
Alabama	642	493	76.8	149	23.2	255	68	26.7	187	73.3
Alaska	38	34	89.5	4	10.5	14	11	78.6	3	21.4
Arizona	874	733	83.9	141	16.1	521	436	83.7	85	16.3
Arkansas	307	249	81.1	58	18.9	180	159	88.3	21	11.7
California	4,693	3,869	82.4	824	17.6	2,118	1,853	87.5	265	12.5
Colorado	430	362	84.2	68	15.8	224	187	83.5	37	16.5
Connecticut	224	187	83.5	37	16.5	94	79	84.0	15	16.0
Delaware	128	106	82.8	22	17.2	54	46	85.2	8	14.8
District of Columbia	183	158	86.3	25	13.7	116	98	84.5	18	15.5
Florida	4,473	3,723	83.2	750	16.8	2,884	2,402	83.3	482	16.7
Georgia	2,558	2,076	81.2	482	18.8	1,146	977	85.3	169	14.7
Hawaii	77	66	85.7	11	14.3	25	20	80.0	5	20.0
Illinois	1,278	1,068	83.6	210	16.4	598	510	85.3	88	14.7
Indiana	610	471	77.2	139	22.8	356	273	76.7	83	23.3
Iowa	119	109	91.6	10	8.4	77	73	94.8	4	5.2
Kansas	133	118	88.7	15	11.3	79	64	81.0	15	19.0
Kentucky	406	317	78.1	89	21.9	223	182	81.6	41	18.4
Louisiana	858	677	78.9	181	21.1	450	379	84.2	71	15.8
Maine	40	37	92.5	3	7.5	19	18	94.7	1	5.3
Maryland	749	643	85.8	106	14.2	359	318	88.6	41	11.4
Massachusetts	437	386	88.3	51	11.7	193	180	93.3	13	6.7
Michigan	630	542	86.0	88	14.0	364	300	82.4	64	17.6
Minnesota	261	226	86.6	35	13.4	164	148	90.2	16	9.8
Mississippi	432	227	52.5	205	47.5	201	151	75.1	50	24.9
Missouri	509	412	80.9	97	19.1	277	231	83.4	46	16.6
Montana	11	8	72.7	3	27.3	11	10	90.9	1	9.1
Nebraska	89	77	86.5	12	13.5	53	46	86.8	7	13.2
Nevada	533	473	88.7	60	11.3	274	230	83.9	44	16.1
New Hampshire	28	20	71.4	8	28.6	13	9	69.2	4	30.8
New Mexico	77	69	89.6	8	10.4	12	8	66.7	4	33.3
New York	2,219	1,928	86.9	291	13.1	1,189	1,026	86.3	163	13.7
North Carolina	1,353	1,086	80.3	267	19.7	709	565	79.7	144	20.3
North Dakota	34	30	88.2	4	11.8	3	2	66.7	1	33.3
Ohio	853	698	81.8	155	18.2	453	375	82.8	78	17.2
Oklahoma	394	318	80.7	76	19.3	137	121	88.3	16	11.7
Oregon	249	207	83.1	42	16.9	117	106	90.6	11	9.4
Rhode Island	66	62	93.9	4	6.1	23	21	91.3	2	8.7
South Carolina	722	570	78.9	152	21.1	493	432	87.6	61	12.4
South Dakota	40	28	70.0	12	30.0	26	25	96.2	1	3.8
Tennessee	860	601	69.9	259	30.1	450	303	67.3	147	32.7
Texas	4,892	3,912	80.0	980	20.0	2,514	2,035	80.9	479	19.1
Utah	151	122	80.8	29	19.2	76	64	84.2	12	15.8
Vermont	4	4	100	0	0.0	7	6	85.7	1	14.3
Virginia	832	683	82.1	149	17.9	448	377	84.2	71	15.8
Washington	502	442	88.0	60	12.0	224	192	85.7	32	14.3
West Virginia	139	86	61.9	53	38.1	54	34	63.0	20	37.0
Wisconsin	290	260	89.7	30	10.3	152	140	92.1	12	7.9
Wyoming	13	12	92.3	1	7.7	10	9	90.0	1	10.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through September 2023, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

**Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2022 through June 2023—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)**

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	<b>2022</b>				
<b>Arizona</b>					
Maricopa County	587	492	83.8	95	16.2
<b>California</b>					
Alameda County	201	175	87.1	26	12.9
Los Angeles County	1,496	1,215	81.2	281	18.8
Orange County	254	215	84.6	39	15.4
Riverside County	313	251	80.2	62	19.8
Sacramento County	194	163	84.0	31	16.0
San Bernardino County	286	204	71.3	82	28.7
San Diego County	391	321	82.1	70	17.9
San Francisco County	213	193	90.6	20	9.4
<b>District of Columbia</b>	183	158	86.3	25	13.7
<b>Florida</b>					
Broward County	598	487	81.4	111	18.6
Duval County	287	210	73.2	77	26.8
Hillsborough County	297	249	83.8	48	16.2
Miami-Dade County	1,095	919	83.9	176	16.1
Orange County	424	345	81.4	79	18.6
Palm Beach County	294	257	87.4	37	12.6
Pinellas County	116	100	86.2	16	13.8
<b>Georgia</b>					
Cobb County	176	149	84.7	27	15.3
DeKalb County	362	297	82.0	65	18.0
Fulton County	525	429	81.7	96	18.3
Gwinnett County	220	182	82.7	38	17.3
<b>Illinois</b>					
Cook County	855	721	84.3	134	15.7
<b>Indiana</b>					
Marion County	248	197	79.4	51	20.6
<b>Louisiana</b>					
East Baton Rouge Parish	132	114	86.4	18	13.6
Orleans Parish	126	103	81.7	23	18.3
<b>Maryland</b>					
Baltimore City	161	139	86.3	22	13.7
Montgomery County	106	92	86.8	14	13.2
Prince George's County	251	220	87.6	31	12.4
<b>Massachusetts</b>					
Suffolk County	116	104	89.7	12	10.3
<b>Michigan</b>					
Wayne County	247	205	83.0	42	17.0
<b>Nevada</b>					
Clark County	488	433	88.7	55	11.3
<b>New York</b>					
Bronx County	395	333	84.3	62	15.7
Kings County	477	426	89.3	51	10.7
New York County	326	269	82.5	57	17.5
Queens County	370	334	90.3	36	9.7

**Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2022 through June 2023—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)**

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
<b>2022 (<i>cont</i>)</b>					
<b>North Carolina</b>					
Mecklenburg County	276	221	80.1	55	19.9
<b>Ohio</b>					
Cuyahoga County	118	99	83.9	19	16.1
Franklin County	193	162	83.9	31	16.1
Hamilton County	93	79	84.9	14	15.1
<b>Pennsylvania</b>					
Philadelphia County	376	303	80.6	73	19.4
<b>Tennessee</b>					
Shelby County	339	220	64.9	119	35.1
<b>Texas</b>					
Bexar County	353	277	78.5	76	21.5
Dallas County	911	703	77.2	208	22.8
Harris County	1,278	1,008	78.9	270	21.1
Tarrant County	331	267	80.7	64	19.3
Travis County	244	214	87.7	30	12.3
<b>Washington</b>					
King County	259	235	90.7	24	9.3
<b>2023 (January–June)</b>					
<b>Arizona</b>					
Maricopa County	352	296	84.1	56	15.9
<b>California</b>					
Alameda County	99	87	87.9	12	12.1
Los Angeles County	699	607	86.8	92	13.2
Orange County	124	109	87.9	15	12.1
Riverside County	138	117	84.8	21	15.2
Sacramento County	78	69	88.5	9	11.5
San Bernardino County	133	97	72.9	36	27.1
San Diego County	166	156	94.0	10	6.0
San Francisco County	94	89	94.7	5	5.3
<b>District of Columbia</b>	116	98	84.5	18	15.5
<b>Florida</b>					
Broward County	392	314	80.1	78	19.9
Duval County	174	137	78.7	37	21.3
Hillsborough County	228	195	85.5	33	14.5
Miami-Dade County	695	579	83.3	116	16.7
Orange County	278	232	83.5	46	16.5
Palm Beach County	160	133	83.1	27	16.9
Pinellas County	100	81	81.0	19	19.0
<b>Georgia</b>					
Cobb County	86	73	84.9	13	15.1
DeKalb County	150	137	91.3	13	8.7
Fulton County	212	182	85.8	30	14.2
Gwinnett County	88	79	89.8	9	10.2
<b>Illinois</b>					
Cook County	399	341	85.5	58	14.5

**Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged  $\geq 13$  years, by area of residence, January 2022 through June 2023—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)**

Area of residence	Total diagnoses	$\geq 1$ CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	<b>2023 (January–June) (<i>cont</i>)</b>				
<b>Indiana</b>					
Marion County	143	120	83.9	23	16.1
<b>Louisiana</b>					
East Baton Rouge Parish	69	60	87.0	9	13.0
Orleans Parish	59	51	86.4	8	13.6
<b>Maryland</b>					
Baltimore City	85	77	90.6	8	9.4
Montgomery County	55	48	87.3	7	12.7
Prince George's County	104	93	89.4	11	10.6
<b>Massachusetts</b>					
Suffolk County	59	56	94.9	3	5.1
<b>Michigan</b>					
Wayne County	143	109	76.2	34	23.8
<b>Nevada</b>					
Clark County	241	203	84.2	38	15.8
<b>New York</b>					
Bronx County	197	162	82.2	35	17.8
Kings County	231	191	82.7	40	17.3
New York County	161	131	81.4	30	18.6
Queens County	220	203	92.3	17	7.7
<b>North Carolina</b>					
Mecklenburg County	149	129	86.6	20	13.4
<b>Ohio</b>					
Cuyahoga County	76	66	86.8	10	13.2
Franklin County	111	92	82.9	19	17.1
Hamilton County	57	50	87.7	7	12.3
<b>Pennsylvania</b>					
Philadelphia County	190	162	85.3	28	14.7
<b>Tennessee</b>					
Shelby County	165	97	58.8	68	41.2
<b>Texas</b>					
Bexar County	170	127	74.7	43	25.3
Dallas County	427	333	78.0	94	22.0
Harris County	698	579	83.0	119	17.0
Tarrant County	186	153	82.3	33	17.7
Travis County	117	111	94.9	6	5.1
<b>Washington</b>					
King County	93	80	86.0	13	14.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/ $\mu$ L) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

*Note.* Linkage to HIV medical care was measured by documentation of  $\geq 1$  CD4 or VL tests  $\leq 1$  month after HIV diagnosis. Data are based on residence at time of diagnosis of HIV infection. Data are for cases reported to CDC through September 2023, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

**Table 3a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged ≥ 16 years, by selected characteristics—United States**

	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
<b>2019</b>			
<b>Sex at birth</b>			
Male	254,556	989,200	25.7
Female	21,095	227,010	9.3
<b>Age (yr)</b>			
16–24	36,969	246,290	15.0
25–34	112,897	434,680	26.0
35–44	64,004	238,470	26.8
45–54	37,485	173,420	21.6
≥55	24,439	123,350	19.8
<b>Race/ethnicity<sup>d</sup></b>			
Black/African American	37,499	468,540	8.0
Hispanic/Latino <sup>e</sup>	45,392	312,820	14.5
Other	12,242	131,180	9.3
White	180,661	300,650	60.1
<b>Total</b>	<b>275,794</b>	<b>1,216,210</b>	<b>22.7</b>
<b>2020 (COVID-19 pandemic)</b>			
<b>Sex at birth</b>			
Male	277,576	989,200	28.1
Female	23,680	227,010	10.4
<b>Age (yr)</b>			
16–24	38,399	246,290	15.6
25–34	119,324	434,680	27.5
35–44	72,291	238,470	30.3
45–54	40,867	173,420	23.6
≥55	30,443	123,350	24.7
<b>Race/ethnicity<sup>d</sup></b>			
Black/African American	43,404	468,540	9.3
Hispanic/Latino <sup>e</sup>	51,297	312,820	16.4
Other	12,786	131,180	9.7
White	193,836	300,650	64.5
<b>Total</b>	<b>301,324</b>	<b>1,216,210</b>	<b>24.8</b>

**Table 3a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged ≥ 16 years, by selected characteristics—United States (cont)**

	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2021</b>		
<b>Sex at birth</b>			
Male	338,029	989,200	34.2
Female	28,050	227,010	12.4
<b>Age (yr)</b>			
16–24	47,973	246,290	19.5
25–34	146,753	434,680	33.8
35–44	88,624	238,470	37.2
45–54	46,124	173,420	26.6
≥55	36,885	123,350	29.9
<b>Race/ethnicity<sup>d</sup></b>			
Black/African American	51,833	468,540	11.1
Hispanic/Latino <sup>e</sup>	63,940	312,820	20.4
Other	15,690	131,180	12.0
White	234,896	300,650	78.1
<b>Total</b>	<b>366,359</b>	<b>1,216,210</b>	<b>30.1</b>
	<b>2022</b>		
<b>Sex at birth</b>			
Male	404,503	989,200	40.9
Female	32,801	227,010	14.4
<b>Age (yr)</b>			
16–24	57,930	246,290	23.5
25–34	172,102	434,680	39.6
35–44	108,855	238,470	45.6
45–54	53,402	173,420	30.8
≥55	45,136	123,350	36.6
<b>Race/ethnicity<sup>d</sup></b>			
Black/African American	60,048	468,540	12.8
Hispanic/Latino <sup>e</sup>	76,249	312,820	24.4
Other	19,088	131,180	14.6
White	282,041	300,650	93.8
<b>Total</b>	<b>437,425</b>	<b>1,216,210</b>	<b>36.0</b>

**Table 3a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged ≥ 16 years, by selected characteristics—United States (cont)**

	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2023 (January–June)</b>		
<b>Sex at birth</b>			
Male	354,158	989,200	35.8
Female	26,462	227,010	11.7
<b>Age (yr)</b>			
16–24	39,271	246,290	15.9
25–34	144,988	434,680	33.4
35–44	102,552	238,470	43.0
45–54	49,712	173,420	28.7
≥55	44,214	123,350	35.8
<b>Race/ethnicity<sup>d</sup></b>			
Black/African American	51,195	468,540	10.9
Hispanic/Latino <sup>e</sup>	65,750	312,820	21.0
Other	16,609	131,180	12.7
White	247,183	300,650	82.2
<b>Total</b>	<b>380,737</b>	<b>1,216,210</b>	<b>31.3</b>

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

*Note.* Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

<sup>a</sup> Estimated by using data from IQVIA pharmacy database reported through June 2023 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

<sup>b</sup> Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2018 denominators were used for 2019–2023 PrEP coverage data.

<sup>c</sup> PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

<sup>d</sup> Race/ethnicity data were only available for <40% of persons prescribed PrEP in each year. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.

<sup>e</sup> Hispanic/Latino persons can be of any race.

**Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (preliminary)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
		<b>2019</b>	
Alabama	1,835	11,020	16.7
Alaska	225	1,780	12.6
Arizona	4,584	25,780	17.8
Arkansas	730	5,130	14.2
California	41,672	165,030	25.3
Colorado	4,404	25,120	17.5
Connecticut	2,672	9,560	27.9
Delaware	492	4,400	11.2
District of Columbia	5,935	12,950	45.8
Florida	21,904	125,330	17.5
Georgia	8,686	39,030	22.3
Hawaii	820	4,360	18.8
Idaho	482	4,790	10.1
Illinois	16,659	55,860	29.8
Indiana	2,983	22,170	13.5
Iowa	1,409	4,760	29.6
Kansas	900	5,060	17.8
Kentucky	1,610	12,990	12.4
Louisiana	3,912	15,920	24.6
Maine	649	3,950	16.4
Maryland	4,935	27,300	18.1
Massachusetts	9,323	24,900	37.4
Michigan	4,316	29,570	14.6
Minnesota	4,188	21,720	19.3
Mississippi	944	4,530	20.8
Missouri	3,471	18,370	18.9
Montana	267	2,290	11.7
Nebraska	612	2,180	28.1
Nevada	2,199	11,390	19.3
New Hampshire	616	3,020	20.4
New Jersey	5,716	25,280	22.6
New Mexico	1,077	6,800	15.8
New York	35,608	72,640	49.0
North Carolina	5,407	32,490	16.6
North Dakota	186	1,520	12.2
Ohio	6,107	40,320	15.1
Oklahoma	1,160	11,030	10.5
Oregon	3,404	19,750	17.2
Pennsylvania	10,105	36,490	27.7
Puerto Rico	333	9,700	3.4
Rhode Island	1,092	3,880	28.1
South Carolina	1,719	10,390	16.5
South Dakota	149	910	16.4
Tennessee	3,897	22,460	17.4
Texas	23,192	123,790	18.7
Utah	2,036	6,840	29.8
Vermont	338	1,060	31.9
Virginia	4,401	31,430	14.0
Washington	9,920	40,050	24.8
West Virginia	570	5,250	10.9
Wisconsin	2,476	12,980	19.1
Wyoming	93	890	10.4

**Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2020 (COVID-19 pandemic)</b>		
Alabama	1,910	11,020	17.3
Alaska	240	1,780	13.5
Arizona	5,068	25,780	19.7
Arkansas	867	5,130	16.9
California	42,274	165,030	25.6
Colorado	4,815	25,120	19.2
Connecticut	2,474	9,560	25.9
Delaware	489	4,400	11.1
District of Columbia	6,029	12,950	46.6
Florida	34,693	125,330	27.7
Georgia	9,781	39,030	25.1
Hawaii	904	4,360	20.7
Idaho	664	4,790	13.9
Illinois	15,979	55,860	28.6
Indiana	3,193	22,170	14.4
Iowa	1,543	4,760	32.4
Kansas	944	5,060	18.7
Kentucky	1,663	12,990	12.8
Louisiana	3,567	15,920	22.4
Maine	665	3,950	16.8
Maryland	4,808	27,300	17.6
Massachusetts	9,398	24,900	37.7
Michigan	4,618	29,570	15.6
Minnesota	4,201	21,720	19.3
Mississippi	1,091	4,530	24.1
Missouri	3,566	18,370	19.4
Montana	295	2,290	12.9
Nebraska	709	2,180	32.5
Nevada	2,513	11,390	22.1
New Hampshire	649	3,020	21.5
New Jersey	5,933	25,280	23.5
New Mexico	1,235	6,800	18.2
New York	34,435	72,640	47.4
North Carolina	6,154	32,490	18.9
North Dakota	180	1,520	11.8
Ohio	6,797	40,320	16.9
Oklahoma	1,532	11,030	13.9
Oregon	3,818	19,750	19.3
Pennsylvania	10,582	36,490	29.0
Puerto Rico	370	9,700	3.8
Rhode Island	1,167	3,880	30.1
South Carolina	2,095	10,390	20.2
South Dakota	142	910	15.6
Tennessee	5,160	22,460	23.0
Texas	27,564	123,790	22.3
Utah	2,360	6,840	34.5
Vermont	322	1,060	30.4
Virginia	5,107	31,430	16.2
Washington	10,106	40,050	25.2
West Virginia	523	5,250	10.0
Wisconsin	2,532	12,980	19.5
Wyoming	95	890	10.7

**Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
		<b>2021</b>	
Alabama	2,758	11,020	25.0
Alaska	304	1,780	17.1
Arizona	6,582	25,780	25.5
Arkansas	1,271	5,130	24.8
California	50,217	165,030	30.4
Colorado	6,200	25,120	24.7
Connecticut	3,048	9,560	31.9
Delaware	658	4,400	15.0
District of Columbia	6,840	12,950	52.8
Florida	42,739	125,330	34.1
Georgia	12,189	39,030	31.2
Hawaii	1,141	4,360	26.2
Idaho	878	4,790	18.3
Illinois	18,424	55,860	33.0
Indiana	4,234	22,170	19.1
Iowa	1,943	4,760	40.8
Kansas	1,274	5,060	25.2
Kentucky	2,221	12,990	17.1
Louisiana	4,145	15,920	26.0
Maine	905	3,950	22.9
Maryland	5,792	27,300	21.2
Massachusetts	10,156	24,900	40.8
Michigan	5,852	29,570	19.8
Minnesota	5,251	21,720	24.2
Mississippi	1,591	4,530	35.1
Missouri	4,163	18,370	22.7
Montana	392	2,290	17.1
Nebraska	991	2,180	45.5
Nevada	4,882	11,390	42.9
New Hampshire	799	3,020	26.5
New Jersey	7,294	25,280	28.9
New Mexico	1,596	6,800	23.5
New York	39,350	72,640	54.2
North Carolina	7,936	32,490	24.4
North Dakota	245	1,520	16.1
Ohio	8,456	40,320	21.0
Oklahoma	2,323	11,030	21.1
Oregon	4,686	19,750	23.7
Pennsylvania	13,066	36,490	35.8
Puerto Rico	612	9,700	6.3
Rhode Island	1,521	3,880	39.2
South Carolina	2,919	10,390	28.1
South Dakota	217	910	23.8
Tennessee	7,217	22,460	32.1
Texas	34,772	123,790	28.1
Utah	3,257	6,840	47.6
Vermont	480	1,060	45.3
Virginia	6,260	31,430	19.9
Washington	11,391	40,050	28.4
West Virginia	706	5,250	13.4
Wisconsin	2,818	12,980	21.7
Wyoming	135	890	15.2

**Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
		<b>2022</b>	
Alabama	3,435	11,020	31.2
Alaska	397	1,780	22.3
Arizona	8,316	25,780	32.3
Arkansas	1,675	5,130	32.7
California	61,509	165,030	37.3
Colorado	7,611	25,120	30.3
Connecticut	4,001	9,560	41.9
Delaware	852	4,400	19.4
District of Columbia	7,746	12,950	59.8
Florida	46,350	125,330	37.0
Georgia	13,744	39,030	35.2
Hawaii	1,512	4,360	34.7
Idaho	1,075	4,790	22.4
Illinois	21,898	55,860	39.2
Indiana	5,449	22,170	24.6
Iowa	2,198	4,760	46.2
Kansas	1,591	5,060	31.4
Kentucky	3,031	12,990	23.3
Louisiana	4,739	15,920	29.8
Maine	1,120	3,950	28.4
Maryland	6,877	27,300	25.2
Massachusetts	13,010	24,900	52.2
Michigan	7,121	29,570	24.1
Minnesota	6,579	21,720	30.3
Mississippi	1,727	4,530	38.1
Missouri	5,134	18,370	27.9
Montana	533	2,290	23.3
Nebraska	1,260	2,180	57.8
Nevada	5,681	11,390	49.9
New Hampshire	1,038	3,020	34.4
New Jersey	8,934	25,280	35.3
New Mexico	2,032	6,800	29.9
New York	46,046	72,640	63.4
North Carolina	9,976	32,490	30.7
North Dakota	338	1,520	22.2
Ohio	10,338	40,320	25.6
Oklahoma	2,772	11,030	25.1
Oregon	6,053	19,750	30.6
Pennsylvania	16,071	36,490	44.0
Puerto Rico	828	9,700	8.5
Rhode Island	1,831	3,880	47.2
South Carolina	3,649	10,390	35.1
South Dakota	321	910	35.3
Tennessee	8,849	22,460	39.4
Texas	40,707	123,790	32.9
Utah	4,017	6,840	58.7
Vermont	576	1,060	54.3
Virginia	7,542	31,430	24.0
Washington	13,761	40,050	34.4
West Virginia	906	5,250	17.3
Wisconsin	3,348	12,980	25.8
Wyoming	183	890	20.6

**Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2023 (January–June)</b>		
Alabama	2,996	11,020	27.2
Alaska	334	1,780	18.8
Arizona	7,531	25,780	29.2
Arkansas	1,468	5,130	28.6
California	53,082	165,030	32.2
Colorado	6,649	25,120	26.5
Connecticut	3,367	9,560	35.2
Delaware	800	4,400	18.2
District of Columbia	6,884	12,950	53.2
Florida	42,383	125,330	33.8
Georgia	11,663	39,030	29.9
Hawaii	1,307	4,360	30.0
Idaho	856	4,790	17.9
Illinois	19,625	55,860	35.1
Indiana	4,866	22,170	21.9
Iowa	1,877	4,760	39.4
Kansas	1,412	5,060	27.9
Kentucky	2,714	12,990	20.9
Louisiana	4,029	15,920	25.3
Maine	998	3,950	25.3
Maryland	5,989	27,300	21.9
Massachusetts	11,095	24,900	44.6
Michigan	6,047	29,570	20.4
Minnesota	5,716	21,720	26.3
Mississippi	1,337	4,530	29.5
Missouri	4,552	18,370	24.8
Montana	438	2,290	19.1
Nebraska	1,097	2,180	50.3
Nevada	3,950	11,390	34.7
New Hampshire	976	3,020	32.3
New Jersey	7,998	25,280	31.6
New Mexico	1,780	6,800	26.2
New York	40,201	72,640	55.3
North Carolina	8,557	32,490	26.3
North Dakota	302	1,520	19.9
Ohio	9,205	40,320	22.8
Oklahoma	2,136	11,030	19.4
Oregon	5,211	19,750	26.4
Pennsylvania	14,125	36,490	38.7
Puerto Rico	799	9,700	8.2
Rhode Island	1,654	3,880	42.6
South Carolina	3,212	10,390	30.9
South Dakota	272	910	29.9
Tennessee	7,000	22,460	31.2
Texas	35,164	123,790	28.4
Utah	3,625	6,840	53.0
Vermont	500	1,060	47.2
Virginia	6,842	31,430	21.8
Washington	11,862	40,050	29.6
West Virginia	749	5,250	14.3
Wisconsin	2,836	12,980	21.8
Wyoming	156	890	17.5

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

<sup>a</sup> Estimated by using data from IQVIA pharmacy database reported through June 2023 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

<sup>b</sup> Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator.

<sup>c</sup> PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2019</b>		
<b>Arizona</b>			
Maricopa County	3,540	22,720	15.6
<b>California</b>			
Alameda County	2,160	8,930	24.2
Los Angeles County	13,730	67,450	20.4
Orange County	2,025	10,510	19.3
Riverside County	1,820	11,080	16.4
Sacramento County	952	5,920	16.1
San Bernardino County	755	11,890	6.3
San Diego County	3,737	14,500	25.8
San Francisco County	8,848	10,840	81.6
<b>District of Columbia</b>	5,935	12,950	45.8
<b>Florida</b>			
Broward County	3,889	20,470	19.0
Duval County	498	8,970	5.6
Hillsborough County	1,395	12,910	10.8
Miami-Dade County	6,488	21,760	29.8
Orange County	2,791	15,310	18.2
Palm Beach County	888	9,170	9.7
Pinellas County	1,166	9,530	12.2
<b>Georgia</b>			
Cobb County	570	3,070	18.6
DeKalb County	1,545	6,290	24.6
Fulton County	3,311	13,120	25.2
Gwinnett County	686	3,240	21.2
<b>Illinois</b>			
Cook County	13,644	39,060	34.9
<b>Indiana</b>			
Marion County	1,148	9,150	12.5
<b>Louisiana</b>			
East Baton Rouge Parish	489	1,810	27.0
Orleans Parish	1,519	4,590	33.1
<b>Maryland</b>			
Baltimore City	906	6,330	14.3
Montgomery County	893	5,770	15.5
Prince George's County	798	4,040	19.8
<b>Massachusetts</b>			
Suffolk County	2,766	6,520	42.4
<b>Michigan</b>			
Wayne County	1,201	9,270	13.0
<b>Nevada</b>			
Clark County	1,877	11,670	16.1
<b>New Jersey</b>			
Essex County	686	4,090	16.8
Hudson County	1,076	4,650	23.1

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2019 (cont)</b>		
<b>New York</b>			
Bronx County	2,256	5,570	40.5
Kings County	7,662	15,650	49.0
New York County	14,266	15,540	91.8
Queens County	3,890	9,230	42.1
<b>North Carolina</b>			
Mecklenburg County	1,331	8,450	15.8
<b>Ohio</b>			
Cuyahoga County	953	7,520	12.7
Franklin County	2,046	11,620	17.6
Hamilton County	563	7,720	7.3
<b>Pennsylvania</b>			
Philadelphia County	3,673	9,840	37.3
<b>Puerto Rico</b>			
San Juan Municipio <sup>d</sup>	— <sup>d</sup>	2,190	n/a
<b>Tennessee</b>			
Shelby County	637	6,450	9.9
<b>Texas</b>			
Bexar County	1,540	11,920	12.9
Dallas County	4,126	28,670	14.4
Harris County	4,950	40,670	12.2
Tarrant County	1,456	11,340	12.8
Travis County	4,520	11,590	39.0
<b>Washington</b>			
King County	6,932	17,890	38.7

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2020 (COVID-19 pandemic)</b>		
<b>Arizona</b>			
Maricopa County	3,907	22,720	17.2
<b>California</b>			
Alameda County	2,009	8,930	22.5
Los Angeles County	14,750	67,450	21.9
Orange County	2,187	10,510	20.8
Riverside County	1,951	11,080	17.6
Sacramento County	980	5,920	16.6
San Bernardino County	811	11,890	6.8
San Diego County	3,795	14,500	26.2
San Francisco County	8,156	10,840	75.2
<b>District of Columbia</b>	6,029	12,950	46.6
<b>Florida</b>			
Broward County	6,848	20,470	33.5
Duval County	721	8,970	8.0
Hillsborough County	1,541	12,910	11.9
Miami-Dade County	10,241	21,760	47.1
Orange County	3,895	15,310	25.4
Palm Beach County	3,003	9,170	32.7
Pinellas County	1,254	9,530	13.2
<b>Georgia</b>			
Cobb County	656	3,070	21.4
DeKalb County	1,688	6,290	26.8
Fulton County	3,606	13,120	27.5
Gwinnett County	799	3,240	24.7
<b>Illinois</b>			
Cook County	12,916	39,060	33.1
<b>Indiana</b>			
Marion County	1,205	9,150	13.2
<b>Louisiana</b>			
East Baton Rouge Parish	529	1,810	29.2
Orleans Parish	1,334	4,590	29.1
<b>Maryland</b>			
Baltimore City	847	6,330	13.4
Montgomery County	897	5,770	15.5
Prince George's County	822	4,040	20.3
<b>Massachusetts</b>			
Suffolk County	2,807	6,520	43.1
<b>Michigan</b>			
Wayne County	1,217	9,270	13.1
<b>Nevada</b>			
Clark County	2,110	11,670	18.1
<b>New Jersey</b>			
Essex County	719	4,090	17.6
Hudson County	1,074	4,650	23.1

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
<b>2020 (COVID-19 pandemic) (<i>cont</i>)</b>			
<b>New York</b>			
Bronx County	2,080	5,570	37.3
Kings County	7,506	15,650	48.0
New York County	13,873	15,540	89.3
Queens County	3,827	9,230	41.5
<b>North Carolina</b>			
Mecklenburg County	1,564	8,450	18.5
<b>Ohio</b>			
Cuyahoga County	961	7,520	12.8
Franklin County	2,300	11,620	19.8
Hamilton County	632	7,720	8.2
<b>Pennsylvania</b>			
Philadelphia County	3,538	9,840	36.0
<b>Puerto Rico</b>			
San Juan Municipio <sup>d</sup>	--d	2,190	n/a
<b>Tennessee</b>			
Shelby County	816	6,450	12.7
<b>Texas</b>			
Bexar County	1,785	11,920	15.0
Dallas County	5,174	28,670	18.0
Harris County	6,001	40,670	14.8
Tarrant County	1,631	11,340	14.4
Travis County	5,044	11,590	43.5
<b>Washington</b>			
King County	6,997	17,890	39.1

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2021</b>		
<b>Arizona</b>			
Maricopa County	5,051	22,720	22.2
<b>California</b>			
Alameda County	2,200	8,930	24.6
Los Angeles County	18,474	67,450	27.4
Orange County	2,811	10,510	26.7
Riverside County	2,539	11,080	22.9
Sacramento County	1,109	5,920	18.7
San Bernardino County	1,195	11,890	10.1
San Diego County	4,426	14,500	30.5
San Francisco County	8,241	10,840	76.0
<b>District of Columbia</b>	6,840	12,950	52.8
<b>Florida</b>			
Broward County	8,359	20,470	40.8
Duval County	878	8,970	9.8
Hillsborough County	2,070	12,910	16.0
Miami-Dade County	11,433	21,760	52.5
Orange County	4,758	15,310	31.1
Palm Beach County	2,766	9,170	30.2
Pinellas County	1,681	9,530	17.6
<b>Georgia</b>			
Cobb County	843	3,070	27.5
DeKalb County	2,021	6,290	32.1
Fulton County	4,242	13,120	32.3
Gwinnett County	1,011	3,240	31.2
<b>Illinois</b>			
Cook County	14,796	39,060	37.9
<b>Indiana</b>			
Marion County	1,582	9,150	17.3
<b>Louisiana</b>			
East Baton Rouge Parish	590	1,810	32.6
Orleans Parish	1,516	4,590	33.0
<b>Maryland</b>			
Baltimore City	960	6,330	15.2
Montgomery County	1,147	5,770	19.9
Prince George's County	991	4,040	24.5
<b>Massachusetts</b>			
Suffolk County	2,759	6,520	42.3
<b>Michigan</b>			
Wayne County	1,560	9,270	16.8
<b>Nevada</b>			
Clark County	4,288	11,670	36.7
<b>New Jersey</b>			
Essex County	848	4,090	20.7
Hudson County	1,304	4,650	28.0

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2021 (cont)</b>		
<b>New York</b>			
Bronx County	2,125	5,570	38.2
Kings County	8,936	15,650	57.1
New York County	15,856	15,540	102.0
Queens County	4,298	9,230	46.6
<b>North Carolina</b>			
Mecklenburg County	1,951	8,450	23.1
<b>Ohio</b>			
Cuyahoga County	1,265	7,520	16.8
Franklin County	2,733	11,620	23.5
Hamilton County	814	7,720	10.5
<b>Pennsylvania</b>			
Philadelphia County	4,092	9,840	41.6
<b>Puerto Rico</b>			
San Juan Municipio	67	2,190	3.1
<b>Tennessee</b>			
Shelby County	946	6,450	14.7
<b>Texas</b>			
Bexar County	2,360	11,920	19.8
Dallas County	6,583	28,670	23.0
Harris County	7,484	40,670	18.4
Tarrant County	2,090	11,340	18.4
Travis County	5,725	11,590	49.4
<b>Washington</b>			
King County	7,640	17,890	42.7

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2022</b>		
<b>Arizona</b>			
Maricopa County	6,411	22,720	28.2
<b>California</b>			
Alameda County	2,695	8,930	30.2
Los Angeles County	23,360	67,450	34.6
Orange County	3,305	10,510	31.4
Riverside County	3,189	11,080	28.8
Sacramento County	1,375	5,920	23.2
San Bernardino County	1,553	11,890	13.1
San Diego County	5,383	14,500	37.1
San Francisco County	9,121	10,840	84.1
<b>District of Columbia</b>	7,746	12,950	59.8
<b>Florida</b>			
Broward County	8,059	20,470	39.4
Duval County	1,480	8,970	16.5
Hillsborough County	2,628	12,910	20.4
Miami-Dade County	11,221	21,760	51.6
Orange County	5,801	15,310	37.9
Palm Beach County	2,462	9,170	26.8
Pinellas County	2,147	9,530	22.5
<b>Georgia</b>			
Cobb County	954	3,070	31.1
DeKalb County	2,229	6,290	35.4
Fulton County	4,649	13,120	35.4
Gwinnett County	1,147	3,240	35.4
<b>Illinois</b>			
Cook County	17,257	39,060	44.2
<b>Indiana</b>			
Marion County	2,003	9,150	21.9
<b>Louisiana</b>			
East Baton Rouge Parish	620	1,810	34.3
Orleans Parish	1,672	4,590	36.4
<b>Maryland</b>			
Baltimore City	1,115	6,330	17.6
Montgomery County	1,451	5,770	25.1
Prince George's County	1,089	4,040	27.0
<b>Massachusetts</b>			
Suffolk County	3,526	6,520	54.1
<b>Michigan</b>			
Wayne County	1,873	9,270	20.2
<b>Nevada</b>			
Clark County	4,348	11,670	37.3
<b>New Jersey</b>			
Essex County	1,019	4,090	24.9
Hudson County	1,597	4,650	34.3

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2022</b>		
<b>New York</b>			
Bronx County	2,153	5,570	38.7
Kings County	10,446	15,650	66.7
New York County	18,133	15,540	116.7
Queens County	5,207	9,230	56.4
<b>North Carolina</b>			
Mecklenburg County	2,322	8,450	27.5
<b>Ohio</b>			
Cuyahoga County	1,685	7,520	22.4
Franklin County	3,106	11,620	26.7
Hamilton County	986	7,720	12.8
<b>Pennsylvania</b>			
Philadelphia County	5,043	9,840	51.3
<b>Puerto Rico</b>			
San Juan Municipio	122	2,190	5.6
<b>Tennessee</b>			
Shelby County	1,167	6,450	18.1
<b>Texas</b>			
Bexar County	2,860	11,920	24.0
Dallas County	7,221	28,670	25.2
Harris County	8,678	40,670	21.3
Tarrant County	2,484	11,340	21.9
Travis County	6,524	11,590	56.3
<b>Washington</b>			
King County	9,006	17,890	50.3

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
	<b>2023 (January–June)</b>		
<b>Arizona</b>			
Maricopa County	5,815	22,720	25.6
<b>California</b>			
Alameda County	2,233	8,930	25.0
Los Angeles County	20,268	67,450	30.0
Orange County	2,863	10,510	27.2
Riverside County	2,901	11,080	26.2
Sacramento County	1,190	5,920	20.1
San Bernardino County	1,314	11,890	11.1
San Diego County	4,656	14,500	32.1
San Francisco County	7,876	10,840	72.7
<b>District of Columbia</b>	6,884	12,950	53.2
<b>Florida</b>			
Broward County	7,508	20,470	36.7
Duval County	1,812	8,970	20.2
Hillsborough County	2,316	12,910	17.9
Miami-Dade County	10,519	21,760	48.3
Orange County	5,311	15,310	34.7
Palm Beach County	2,329	9,170	25.4
Pinellas County	1,858	9,530	19.5
<b>Georgia</b>			
Cobb County	807	3,070	26.3
DeKalb County	1,878	6,290	29.9
Fulton County	3,924	13,120	29.9
Gwinnett County	965	3,240	29.8
<b>Illinois</b>			
Cook County	15,471	39,060	39.6
<b>Indiana</b>			
Marion County	1,869	9,150	20.4
<b>Louisiana</b>			
East Baton Rouge Parish	513	1,810	28.3
Orleans Parish	1,395	4,590	30.4
<b>Maryland</b>			
Baltimore City	957	6,330	15.1
Montgomery County	1,294	5,770	22.4
Prince George's County	954	4,040	23.6
<b>Massachusetts</b>			
Suffolk County	2,973	6,520	45.6
<b>Michigan</b>			
Wayne County	1,572	9,270	17.0
<b>Nevada</b>			
Clark County	2,890	11,670	24.8
<b>New Jersey</b>			
Essex County	926	4,090	22.6
Hudson County	1,459	4,650	31.4

**Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through June 2023, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (preliminary) (cont)**

Area of residence	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%
<b>2023 (January–June) (cont)</b>			
<b>New York</b>			
Bronx County	1,728	5,570	31.0
Kings County	9,228	15,650	59.0
New York County	15,712	15,540	101.1
Queens County	4,572	9,230	49.5
<b>North Carolina</b>			
Mecklenburg County	1,968	8,450	23.3
<b>Ohio</b>			
Cuyahoga County	1,602	7,520	21.3
Franklin County	2,737	11,620	23.6
Hamilton County	857	7,720	11.1
<b>Pennsylvania</b>			
Philadelphia County	4,436	9,840	45.1
<b>Puerto Rico</b>			
San Juan Municipio	130	2,190	5.9
<b>Tennessee</b>			
Shelby County	1,014	6,450	15.7
<b>Texas</b>			
Bexar County	2,535	11,920	21.3
Dallas County	6,194	28,670	21.6
Harris County	7,460	40,670	18.3
Tarrant County	2,151	11,340	19.0
Travis County	5,613	11,590	48.4
<b>Washington</b>			
King County	7,833	17,890	43.8

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

<sup>a</sup> Estimated by using data from IQVIA pharmacy database reported through June 2023 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported.

<sup>b</sup> Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator.

<sup>c</sup> PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

<sup>d</sup> Data value <40 was not reported due to unreliability.

**Table 4. Ending the HIV Epidemic Phase I jurisdictions**

<b>Counties</b>	<b>Territories</b>	<b>States</b>
<b>Arizona</b>	<b>Puerto Rico<sup>a</sup></b>	Alabama
Maricopa County	San Juan Municipio <sup>a</sup>	Arkansas
<b>California</b>		Kentucky
Alameda County		Mississippi
Los Angeles County		Missouri
Orange County		Oklahoma
Riverside County		South Carolina
Sacramento County		
San Bernardino County		
San Diego County		
San Francisco County		
<b>District of Columbia</b>		
<b>Florida</b>		
Broward County		
Duval County		
Hillsborough County		
Miami-Dade County		
Orange County		
Palm Beach County		
Pinellas County		
<b>Georgia</b>		
Cobb County		
DeKalb County		
Fulton County		
Gwinnett County		
<b>Illinois</b>		
Cook County		
<b>Indiana</b>		
Marion County		
<b>Louisiana</b>		
East Baton Rouge Parish		
Orleans Parish		
<b>Maryland</b>		
Baltimore City		
Montgomery County		
Prince George's County		
<b>Massachusetts</b>		
Suffolk County		
<b>Michigan</b>		
Wayne County		
<b>Nevada</b>		
Clark County		
<b>New Jersey<sup>a</sup></b>		
Essex County <sup>a</sup>		
Hudson County <sup>a</sup>		
<b>New York</b>		
Bronx County		
Kings County		
New York County		
Queens County		

**Table 4. Ending the HIV Epidemic Phase I jurisdictions (cont)**

<b>Counties</b>	<b>Territories</b>	<b>States</b>
<b>North Carolina</b>		
Mecklenburg County		
<b>Ohio</b>		
Cuyahoga County		
Franklin County		
Hamilton County		
<b>Pennsylvania<sup>a</sup></b>		
Philadelphia County		
<b>Tennessee</b>		
Shelby County		
<b>Texas</b>		
Bexar County		
Dallas County		
Harris County		
Tarrant County		
Travis County		
<b>Washington</b>		
King County		

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. For more information on the Ending the HIV Epidemic in the U.S. initiative, see <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>.

<sup>a</sup> Linkage to care and viral suppression data are not provided for states and associated jurisdictions that have incomplete reporting of laboratory data to CDC: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.